Stocks Health care INTS
NASDAQ · Health careIntensity Therapeutics, Inc. (INTS)
It posted a net loss of $11.2M. At June 30, 2026 it held $9.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Intensity Therapeutics, Inc.
- Net worth
- Intensity Therapeutics, Inc. has a market value (market cap) of $10.1M at the latest share price, and shareholders' equity of $9.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $9.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Intensity Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Intensity Therapeutics, Inc. does
Intensity Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INTS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.6M | -$8.56 | n/a |
| 2024 | n/a | -$16.3M | -$29.24 | n/a |
| 2023 | n/a | -$10.5M | -$34.49 | n/a |
| 2023 | n/a | -$7.6M | -$55.48 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Intensity Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026
- August 11, 2026
- July 8, 2026
- June 16, 2026
- May 7, 2026
- May 7, 2026
- April 30, 2026
- April 30, 2026Additional proxy material DEFA14A
- April 30, 2026Proxy statement DEF 14A
- March 27, 2026
Insider trades
What the people running Intensity Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Talamo JosephChief Financial Officer | Received as pay | 1,093 | $3.8K |
| June 30, 2026 | Wesolowski John MPrincipal Accounting Officer | Received as pay | 3,688 | $12.9K |
| March 26, 2026 | Bender Lewis HPresident and CEO, Director | Received as pay | 37,749 | $230.6K |
| December 31, 2025 | Talamo JosephChief Financial Officer | Received as pay | 14,482 | $3.8K |
| December 31, 2025 | Wesolowski John MPrincipal Accounting Officer | Received as pay | 8,918 | $2.3K |
Who owns INTS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
3 insiders reported holding 127,890 shares in total, about $395.2K at the last price.
| Holder | Shares |
|---|---|
| Bender Lewis HPresident and CEO, Director | 118,549 |
| Wesolowski John MPrincipal Accounting Officer | 7,102 |
| Talamo JosephChief Financial Officer | 2,239 |
Questions about INTS
What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as INTS. Its shares trade on NASDAQ under the ticker INTS.
What is Intensity Therapeutics, Inc.'s net worth?
Intensity Therapeutics, Inc. has a market value (market cap) of $10.1M at the latest share price, and shareholders' equity of $9.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Intensity Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.2M.
When did Intensity Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.
When is Intensity Therapeutics, Inc.'s next earnings report?
Intensity Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare INTS with
Follow INTS
Get an email when Intensity Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Intensity Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.